Information Provided By:
Fly News Breaks for September 11, 2019
Sep 11, 2019 | 08:20 EDT
SunTrust analyst David MacDonald raised his price target on DaVita to $68 after its Capital Market Day, highlighting the company's "core Kidney Care trends, growth opportunities, capital deployment and 2022 guidance." The analyst notes that while the company is facing some near-term headwinds, he is positive on its improving capital efficiency and the opportunities around home therapy, along with its international business that looks "posed for growth". MacDonald maintains his Hold rating on DaVida however given the labor and ballot initiative industry pressures as well as its slowing organic volume trends.
News For DVA From the Last 2 Days
There are no results for your query DVA